<DOC>
	<DOCNO>NCT01386268</DOCNO>
	<brief_summary>To obtain data safety , efficacy , tolerability KOGENATE FS real-life condition register indication . The observation period patient 6 month .</brief_summary>
	<brief_title>Kogenate FS Regulatory Post-Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients diagnosis hemophilia A Treated KOGENATE FS source FVIII , decision take investigator administer KOGENATE FS Signed informed consent form participate study . For pretreated patient 100 exposure day inhibitor assessment within three month prior enrollment available For pretreated patient le 100 exposure day inhibitor assessment baseline available For patient available inhibitor status , check per recommendation KFDA Patients define include study document prescription KOGENATE FS physician . Patients hypersensitivity ingredient KOGENATE FS protein mouse hamster exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Kogenate FS</keyword>
	<keyword>Hemophilia A</keyword>
</DOC>